Tomer Wasserman
New York,New York
Summary
Global oncology executive (MD/MBA) with over 15 years of leadership in Medical Affairs, Commercial Strategy, and Clinical Development within top-tier pharmaceutical and biotechnology firms. Currently orchestrating Lifecycle Management as Asset Development Lead and Head of Global Medical Affairs for Solid Tumors, overseeing integrated asset strategy across development, medical, commercial, and regulatory functions. Proven track record in lifecycle management, with comprehensive asset ownership from pipeline strategy to global launch and post-market optimization, including five major oncology product launches across breast cancer, lung cancer, and immuno-oncology.
Overview
21
21
years of professional experience
1
1
Certification
Work History
Vice President, Head of Global Medical Affairs -- Solid Tumors
Stemline Therapeutics
06.2023 - Current
- Dual-hatted leadership as Lifecycle Lead (Asset Development Lead) and Head of Global Medical Affairs for ORSERDU (elacestrant), owning the integrated asset strategy across Clinical Development, Medical Affairs, Commercial, and Regulatory functions -- from indication expansion through global market optimization.
- Lead a 15-member global medical affairs organization for the solid tumors portfolio, driving scientific engagement, evidence generation, and lifecycle medical planning across US, Western Europe, and Asia-Pacific (APAC) expansion markets.
- Built the global medical affairs function from the ground up, establishing organizational infrastructure, governance frameworks, and the cross-functional operating model required to support ORSERDU through pivotal regulatory submissions and geographic expansion into Western EU and APAC.
- As Lifecycle Lead, direct the integrated development and commercialization roadmap for ORSERDU, partnering with Research and Development (R&D) on trial design, endpoint selection, and translational science initiatives to advance next-generation indications and combination therapies in ESR1-mutated breast cancer.
- Architected the global Key Opinion Leader (KOL) engagement and scientific platform strategy, driving advisory board programs, congress presence, and publication planning to establish ORSERDU as a differentiated option in the ER-positive/HER2-negative (ER+/HER2-) advanced breast cancer landscape.
- Stemline Therapeutics, a Menarini Group Company
Global Commercial Lead, Solid Tumors
Stemline Therapeutics
01.2022 - 05.2023
- Owned the end-to-end global commercial strategy for ORSERDU (elacestrant) in ESR1-mutated ER-positive/HER2-negative advanced breast cancer, building the launch blueprint from pre-approval through go-to-market execution, contributing to a trajectory toward $0.5B in revenue within two years of launch.
- Developed the global brand positioning and competitive strategy against CDK4/6 inhibitors and fulvestrant, defining the segmentation model and market-shaping narrative that established ORSERDU as a differentiated treatment option in a crowded landscape.
- Secured a landmark GBA (Gemeinsamer Bundesausschuss) pricing decision in Germany based on subgroup analysis, demonstrating the ability to leverage clinical evidence and health economics to achieve favorable reimbursement outcomes in Europe's most rigorous Health Technology Assessment (HTA) environment.
- Led cross-functional commercial readiness across Marketing, Sales, Market Access, and Medical Affairs, aligning launch sequencing with regulatory timelines and clinical data milestones for synchronized US and ex-US execution.
- Designed the global market access and payer engagement strategy, building health economic models and value dossiers to support formulary inclusion and reimbursement across diverse regulatory environments worldwide.
- Stemline Therapeutics, a Menarini Group Company
Global Commercial Director, Immuno-Oncology
AstraZeneca
07.2020 - 12.2021
- Drove global commercial strategy for IMFINZI (durvalumab) in resectable Non-Small Cell Lung Cancer (NSCLC), leading lifecycle management, indication expansion planning, and competitive positioning for one of AstraZeneca's highest-priority immuno-oncology assets.
- Led cross-functional global teams to develop indication sequencing strategies and market-shaping initiatives for IMFINZI in the perioperative NSCLC setting, ahead of pivotal data readouts and regulatory submissions.
- Partnered with Global Medical Affairs and Research and Development (R&D) to align commercial insights with clinical development priorities, ensuring market-informed trial design and evidence generation strategies for the resectable lung cancer franchise.
- Spearheaded global launch readiness for new IMFINZI indications, coordinating across US, EU, Asia-Pacific (APAC), and Middle East and Africa (MEA) regions to ensure synchronized market access strategies, payer engagement, and field force preparedness.
- Oncology Business Unit
South LatAm Cluster Business Unit Director, Oncology
AstraZeneca
, LATAM
01.2019 - 06.2020
- Full Profit and Loss (P&L) ownership for AstraZeneca's oncology business across the South Latin America cluster, leading a high-performance team of 50+ professionals spanning Sales, Marketing, Medical Affairs, and Market Access.
- Delivered +300% revenue growth within 18 months by executing an aggressive multi-brand portfolio expansion strategy across IMFINZI (durvalumab), TAGRISSO (osimertinib), CALQUENCE (acalabrutinib), and LYNPARZA (olaparib), securing critical formulary and reimbursement wins across Argentina, Chile, and neighboring markets.
- Orchestrated simultaneous regional launches and market access strategies for four oncology assets across distinct therapeutic areas (lung cancer, hematology, gynecologic oncology), navigating complex regulatory environments and building innovative patient access programs in resource-constrained settings.
- Transformed the business unit operating model from a legacy structure to an agile, cross-functional team framework, accelerating decision-making speed and improving commercial execution across diverse markets with distinct payer and competitive landscapes.
- Championed multicultural leadership across geographies, adapting global brand strategies for local market relevance while maintaining scientific and commercial integrity across the portfolio.
- Oncology Business Unit
Marketing Unit Manager, Lung Cancer
Roche
, LATAM
09.2016 - 12.2018
- Led the LATAM commercial strategy and regional launch execution for two foundational immuno-oncology and targeted therapy assets, establishing Roche's competitive position in the rapidly evolving Non-Small Cell Lung Cancer (NSCLC) landscape.
- Developed and implemented the go-to-market strategy for TECENTRIQ across multiple lung cancer indications, building the brand architecture, segmentation model, and Key Opinion Leader (KOL) engagement plans for first-in-class cancer immunotherapy (CIT) positioning.
- Drove market access and reimbursement strategies across LATAM markets, securing formulary listings and building innovative patient access programs to maximize reach in both public and private healthcare systems.
- Managed cross-functional teams across Medical Affairs, Regulatory Affairs, Market Access, and Sales to ensure coordinated launch execution, consistent scientific messaging, and rapid competitive response.
- Oncology Business Unit
Market Access Operations Manager, Oncology
Roche
, LATAM
06.2015 - 08.2016
- Market Access and Government Affairs
Oncology Product Manager, Breast Cancer
Roche
, LATAM
08.2012 - 05.2015
- PERJETA (pertuzumab) | HERCEPTIN (trastuzumab) | Herceptin SC (subcutaneous) | KADCYLA (ado-trastuzumab emtansine)
- Oncology Business Unit
Area Cardiometabolism Medical Lead / Medical Manager
Roche
, LATAM
01.2011 - 05.2012
- Medical Affairs and Special Products
Clinical Research Site Manager and Principal Investigator
Sanatorio de la Providencia
Argentina
01.2007 - 04.2011
- Managed daily operations of facility ensuring compliance with health regulations.
- Delegated work to staff, setting priorities and goals.
ICU Chief and Emergency Room Chief
Sanatorio de la Providencia
Argentina
01.2005 - 01.2010
- Directed daily operations and staff management in healthcare setting.
- Implemented patient care protocols ensuring compliance with health standards.
- Managed departmental budgets and resource allocation effectively.
Education
Certificate Programs - Clinical Drug Development, Drug Discovery and Development, Cancer Genomics and Precision Medicine, Immuno-Oncology and CAR-T Cell Therapies
Harvard Medical School
Boston, MA12.2024
Executive Programs - Executive Strategy Program, Pharmaceutical Management, Strategic Marketing Management, Strategic Negotiation
Buenos Aires12.2021
Postgraduate Clinical Training - Cardiology, Critical Care Medicine, Pharma-Economics and Health Technology Assessment (HTA)
Universidad Favaloro, Universidad de Buenos Aires, IECS
Buenos Aires, Argentina12.2007
Doctor of Medicine (MD) -
Universidad Favaloro
Buenos Aires, ArgentinaExecutive Master of Business Administration (MBA) - Strategic Management
UADE Business School
Buenos Aires, ArgentinaSkills
* Cross-Functional Team Leadership
* Multicultural Global Leadership
* Oncology Portfolio Strategy
* Clinical Development
* Drug development
* Business Development
* Strategic Partnerships
* Regulatory Framework
* Key Expert / Opinion Leader (KOL) Engagement
* Medical Affairs Leadership
* Immuno-Oncology
* Precision Medicine
* Advisory Boards
* Oncology
* Clinical Evidence Generation
* Real World Evidence Generation
* Publication Planning
* Profit and Loss (P&L) Ownership
* Commercial Launch Excellence
* Brand Positioning
* Access
* Forecasting
Certification
- Clinical Drug Development, Harvard Medical School, 2024
- Drug Discovery and Development, Harvard Medical School, 2024
- Cancer Genomics and Precision Medicine, Harvard Medical School, 2020
- Immuno-Oncology and CAR-T Cell Therapies, Harvard Medical School, 2020
Postgraduate Clinical Training
- Cardiology, Universidad Favaloro, 2006-2007
- Critical Care Medicine, National Board, Universidad de Buenos Aires, 2003-2006
- Pharma-Economics and Health Technology Assessment (HTA), IECS, Buenos Aires, 2012-2013
Executive Programs
- Executive Strategy Program, Said Business School, Oxford University, 2021
- Pharmaceutical Management, Cornell University, 2020
- Strategic Marketing Management, Harvard Business School, 2014
- Strategic Negotiation, EADEE, Buenos Aires, 2013
Timeline
Vice President, Head of Global Medical Affairs -- Solid Tumors
Stemline Therapeutics
06.2023 - Current
Global Commercial Lead, Solid Tumors
Stemline Therapeutics
01.2022 - 05.2023
Global Commercial Director, Immuno-Oncology
AstraZeneca
07.2020 - 12.2021
South LatAm Cluster Business Unit Director, Oncology
AstraZeneca
01.2019 - 06.2020
Marketing Unit Manager, Lung Cancer
Roche
09.2016 - 12.2018
Market Access Operations Manager, Oncology
Roche
06.2015 - 08.2016
Oncology Product Manager, Breast Cancer
Roche
08.2012 - 05.2015
Area Cardiometabolism Medical Lead / Medical Manager
Roche
01.2011 - 05.2012
Clinical Research Site Manager and Principal Investigator
Sanatorio de la Providencia
01.2007 - 04.2011
ICU Chief and Emergency Room Chief
Sanatorio de la Providencia
01.2005 - 01.2010
Certificate Programs - Clinical Drug Development, Drug Discovery and Development, Cancer Genomics and Precision Medicine, Immuno-Oncology and CAR-T Cell Therapies
Harvard Medical School
Executive Programs - Executive Strategy Program, Pharmaceutical Management, Strategic Marketing Management, Strategic Negotiation
Postgraduate Clinical Training - Cardiology, Critical Care Medicine, Pharma-Economics and Health Technology Assessment (HTA)
Universidad Favaloro, Universidad de Buenos Aires, IECS
Doctor of Medicine (MD) -
Universidad Favaloro
Executive Master of Business Administration (MBA) - Strategic Management
UADE Business School